Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Värmeförsök (HER2 antikroppsterapi med lutetium-177) (RAD202)

21 september 2026 uppdaterad av: Radiopharm Theranostics, Ltd

Fas 0/1 studie av säkerheten och tolerabiliteten från 177LU-Rad202, en lutetium-177 radiomärkt enstaka domän-antikropp mot human epidermal tillväxtfaktorreceptor 2 hos patienter med avancerade fasta tumörer

This is a first-in-human, Phase 0/1, open-label study of177Lu-RAD202 to determine the recommended dose(s) for future exploration of 177Lu-RAD202 in participants with HER2 expressing advanced solid tumours.

Studieöversikt

Status

Rekrytering

Intervention / Behandling

Detaljerad beskrivning

This is a first-in-human, Phase 0/1, open-label study of 177Lu-RAD202 consisting of a Screening Period, a Treatment Period with 177Lu-RAD202 and a Safety and Long-Term Follow-Up Period to determine the recommended dose(s) for future exploration of 177Lu-RAD202 in participants with HER2 expressing advanced solid tumours.

Screening Period: Screening period of up to 4 weeks Phase I (Treatment Period): 177Lu-RAD202 dose escalation

  • Treatment Period with each cycle lasting 6 weeks. Extension of the planned dose intervals are possible following discussion and agreement between the Sponsor and Investigator.
  • Participants may be treated with multiple cycles as long as they appear to derive clinical benefit as determined by the Investigator and provided adequate clinical safety and organ dosimetry data.
  • DLT observation period for 177Lu-RAD202 is 6 weeks following first injection of 177Lu-RAD202.
  • Should an alternative treatment schedule be explored, the DLT observation period for 177Lu-RAD202 at that dose level will be the proposed cycle duration.

Safety Follow-Up Period:

  • An End of Treatment Visit performed within 7 days of the last dose of 177Lu-RAD202
  • A Safety Follow-up Visit performed every 12 ± 2 weeks from the End of Treatment Visit

Studietyp

Interventionell

Inskrivning (Beräknad)

30

Fas

  • Tidig fas 1

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

    • New South Wales
      • Kingswood, New South Wales, Australien, 2747
      • Macquarie Park, New South Wales, Australien, 2109
      • Wollongong, New South Wales, Australien, 2500
    • Victoria
      • Fitzroy, Victoria, Australien, 3065
        • Rekrytering
        • St Vincents Hospital, Melbourne
        • Kontakt:
    • Western Australia
      • Murdoch, Western Australia, Australien, 6150

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  1. Aged 18 years and older.

  2. Written, voluntary, informed consent of the participants must be obtained in compliance with institutional, regional, and federal guidelines.

  3. Participants with histologically or cytologically confirmed, HER2 positive or HER2-low, advanced solid tumours that are relapsed/refractory, locally advanced not amenable to curative-intent therapy, or metastatic, with documented disease progression during or after their most recent line of anti-cancer therapy. Participants must be refractory to or intolerant of standard of care therapy or have no standard of care therapy available that is likely to provide clinical benefit.

    Participant HER2 positivity is determined by local testing and is defined as a score of 3+ on immunohistochemical analysis IHC), or, defined as a score of 2+ on IHC and positive results on in situ hybridisation (ISH). HER2-low is defined as a score of 1+ on IHC analysis or a score of 2+ on IHC analysis with ISH negative. If the participant tumor's HER2 status is unknown, it may be determined in a pre-screening step whereby the participant is asked to provide written informed consent to have their tumor tissue undergo IHC testing as determined by a validated test (tumor tissue may be obtained from archived samples or from a freshly obtained biopsy).

  4. Must have at least 1 measurable target lesion according to RECIST version 1.1.

  5. Eastern Cooperative Oncology Group (ECOG) performance status ≤2.

  6. Participants must have a life expectancy of ≥4 months in the opinion of the Investigator.

  7. Women of childbearing potential (WOCBP) must have a negative serum beta-human chorionic gonadotropin (β-hCG) test and must not be breastfeeding. WOCBP are defined as those who are not surgically sterile or post-menopausal. Female participants will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause.

  8. WOCBP must agree to use a highly effective method of contraception during the study and for 90 days after the last dose of 177Lu-RAD202. Acceptable methods of contraception are described in Section 12.3.3 of the Protocol.

  9. Male participants who are able to father a child must agree to avoid impregnating a partner and to adhere to a highly effective method of contraception during the study and for 90 days after the last dose of 177Lu-RAD202. All male participants must agree to not donate sperm during the study and at least 90 days after the last dose of 177Lu-RAD202, whichever occurs later. Acceptable methods of contraception are described in Section 12.3.3 of the Protocol.

  10. Participants with previously treated brain metastases are eligible to participate if:

    1. They are neurologically and radiologically stable (no evidence of progression by imaging; same imaging modality [magnetic resonance imaging (MRI) or computed tomography (CT) scan] must be used for each assessment),
    2. Do not require corticosteroids to treat associated neurological symptoms, and
    3. Participants have no history of leptomeningeal disease or spinal cord compression.
    4. Participants with active brain metastases untreated with brain-directed therapy such as radiotherapy, are not eligible.

Exclusion Criteria:

  1. Participants who have any other known, active malignancy, except for treated cervical intraepithelial neoplasia, or nonmelanoma skin cancer. Participants with a history of malignancies of low recurrence potential who have received curative-intent therapy may be approved on a case-by-case basis in discussion with the study Sponsor, if it is determined not to put the participant at an increased risk of adverse drug effects and/or interfere with the integrity of study outcome.

  2. Participants who have any medical condition that would, in the Investigator's judgment, prevent the participant's full participation in the clinical study due to safety concerns or compliance with clinical study procedures such as participants with severe claustrophobia who are unresponsive to oral anxiolytics, participants with low back pain who cannot lie comfortably on an imaging table, participants who are hyperactive or hyperkinetic such that they cannot tolerate lying still for multiple time-point imaging procedures, etc.

  3. Residual toxicity Grade ≥ 2 from previously administered therapy (except for alopecia). Patients with Grade 2 or higher toxicity due to prior treatment may be allowed on a case-by-case basis in discussion with study Sponsor provided it is deemed not to put the participant at a higher risk of treatment-related toxicity or interfere with the integrity of study data, e.g., participants with endocrinopathy on stable replacement therapy

  4. Inadequate organ functions as reflected in laboratory parameters:

    • Creatinine clearance or Body Surface Area (BSA) adjusted Estimated glomerular filtration rate (eGFR) (calculated using any clinically validated formula, preferably Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), or measured) < 60 mL/min
    • Platelet count of < 80 x 109/L
    • Absolute neutrophil count (ANC) < 1.5 x 109/L
    • Haemoglobin < 9 g/dL
    • Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 3 x upper limit of normal (ULN), or > 5 x ULN for participants with known liver metastases
    • Total bilirubin > 1.5 x ULN, except for participants with documented Gilbert's syndrome who are eligible if total bilirubin ≤ 3 x ULN
    • For participants not taking warfarin or other anticoagulants: international normalized ratio (INR) ≥ 1.5 or prothrombin time (PT) ≥ 1.5 × ULN; and either partial thromboplastin time or activated partial thromboplastin time (PTT or aPTT) ≥1.5 × ULN. Participants taking warfarin must be on a stable dose that results in a stable INR < 3.5. Among participants receiving other anticoagulant therapy, PT or aPTT must be within the intended therapeutic range of the anticoagulant.
  5. Significant cardiovascular disease including:

    • Unstable angina and/or myocardial infarction within 6 months prior to screening
    • New York Heart Association Class II or greater congestive heart failure
    • Clinically significant abnormalities in rhythm, conduction, or morphology of resting ECG (e.g., complete left bundle branch block, third degree heart block)
    • QT interval corrected for heart rate using Fridericia's formula (QTcF) > 470 msec for females and QTcF > 450 msec for males on screening electrocardiogram (ECG) or congenital long QT syndrome
    • Uncontrolled hypertension
    • Known LVEF < 50%. (LVEF may be performed either by echocardiogram or other appropriate imaging modalities such as nuclear cardiac imaging (MUGA) or MRI).
  6. History of uncontrolled allergic reactions and/or have hypersensitivity to anti-HER2 monoclonal antibodies, kanamycin A or aminoglycoside therapies, or other excipients that may induce hypersensitivity

  7. Pregnant or lactating women

  8. Participants who are receiving any other investigational agents

  9. Received anti-cancer therapy, including chemotherapy, immunotherapy, radiation therapy, biologic, herbal therapy, or any investigational therapy or investigational device, within 28 days (or 5 half-lives for biologic/non-cytotoxic agents, whichever is shorter), prior to the first dose of 177Lu-RAD202.

  10. Has had or is scheduled to have major surgery ≤ 28 days prior to the first dose of 177Lu-RAD202. Surgical procedures not considered to put participants at higher risk of AEs and/or interfere with the integrity of study outcome may be allowed on a case-by-case basis in discussion with the Sponsor.

  11. Positive status for human immunodeficiency virus (HIV).

  12. Active or chronic hepatitis B or C. Chronic hepatitis B or hepatitis C with undetectable viral loads on stable suppression therapy may be allowed on a case-by-case basis in discussion with study Sponsor.

  13. Any medical condition which, in the opinion of the Investigator, places the participant at an unacceptably high risk for toxicities.

  14. Any uncontrolled intercurrent illness or clinically significant uncontrolled condition(s), including but not limited to active bacterial, fungal, or viral infections requiring systemic therapy.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: N/A
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: 177Lu-RAD202

Single-arm, open-label study of 177Lu-RAD202

177Lu-RAD202 administered at treatment doses

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Safety and tolerability of 177Lu-RAD202
Tidsram: 6 weeks

The properties, incidence, nature and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) per Common Terminology Criteria for Adverse Events (CTCAE) v5.0

6 weeks
Recommended dose(s) of 177Lu-RAD202 for future exploration
Tidsram: 6 weeks

Incidence of dose-limiting toxicities (DLTs) during the first 6 weeks following 177Lu-RAD202 injection cycle of treatment

6 weeks

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Preliminary antitumor activity of 177Lu-RAD202
Tidsram: Up to 30 weeks

Objective response rates (ORR) as assessed by RECIST v1.1

Up to 30 weeks
Time Activity Curves (TACs)
Tidsram: 72 hours

Percent of the injected activity vs time for selected organs and tumors

72 hours
Radiation dosimetry of 177Lu-RAD202
Tidsram: 72 hours

Absorbed radiation doses of 177Lu-RAD202tr in critical organs (e.g., kidneys, bone marrow)

72 hours
Pharmacokinetics of 177Lu-RAD202
Tidsram: 72 hours

Half-life of 177Lu-RAD202 in blood

72 hours
Biokinetics of 177Lu-RAD202
Tidsram: 72 hours

Time-integrated activity coefficients of 177Lu-RAD202 in organs and tumor lesions

72 hours

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
To explore the use of SPECT/CT as a measure of preliminary anti-tumor activity of 177Lu-RAD202
Tidsram: Up to 30 weeks

Longitudinal assessments of quantitative tumor uptake of 177Lu-RAD202 using SPECT/CT

Up to 30 weeks
To study the effect of amino acid infusion on 177Lu-RAD202 radiation absorption
Tidsram: Up to 30 weeks

Absorbed radiation doses of 177Lu-RAD202 in critical organs (e.g. kidneys, bone marrow)

Up to 30 weeks
Level of agreement between 177Lu-RAD202 and standard of care imaging
Tidsram: Up to 30 weeks

Standard of care imaging may include but is not limited to 18F-FDG-PET, CT-scan and/or 99mTc-MDP-bone

Up to 30 weeks

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

12 februari 2025

Primärt slutförande (Beräknad)

1 december 2027

Avslutad studie (Beräknad)

1 december 2027

Studieregistreringsdatum

Först inskickad

7 februari 2025

Först inskickad som uppfyllde QC-kriterierna

7 februari 2025

Första postat (Faktisk)

13 februari 2025

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

24 september 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

21 september 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • RAD202.2022.0002

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

produkt tillverkad i och exporterad från U.S.A.

Ja

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera